@marymj7 I was wondering how the risk could be high with a drug that was only approved for one year, when the risk with bisphosphonates is (allegedly) after 3-5 years. But the mechanism of sclerostin inhibition is so different from the mechanism of other anti-resorptives.

I wrote somewhere on this forum about the side effects that came as a surprise once bone drugs were on the market: bisphosphonates and atypical fractures/jaw necrosis, Prolia and rebound, and Evenity raising P1NP for only a couple of weeks- all surprises. On the positive side, actual post-marketing experience with Forteo and Tymlos showed on bone cancers.

I wonder if this early ONJ risk with Evenity was expected by researchers and marketers. It is so new. Medwatch/FDA is helpful. Thank you for sharing this! I did Evenity for 120 days but now Reclast- we'll see...I have one problem tooth!

Hope pharmacist, doctor and dentist can work together to make sure your oral surgery is safe!